Biomea Fusion has reported new preclinical and clinical data from studies assessing icovamenib at the Advanced Technologies & Treatments for Diabetes 2025 conference. Notably, the data showed that, three months after the final dose of icovamenib, patients showed significant improvements in pancreatic ...Den vollständigen Artikel lesen ...
© 2025 Edison Investment Research